-
Mashup Score: 6Genetics of migraine: complexity, implications, and potential clinical applications - 1 month(s) ago
Migraine is a common neurological disorder with large burden in terms of disability for individuals and costs for society. Accurate diagnosis and effective treatments remain priorities. Understanding the genetic factors that contribute to migraine risk and symptom manifestation could improve individual management. Migraine has a strong genetic basis that includes both monogenic and polygenic forms. Some distinct, rare, familial migraine subtypes are caused by pathogenic variants in genes involved in ion transport and neurotransmitter release, suggesting an underlying vulnerability of the excitatory–inhibitory balance in the brain, which might be exacerbated by disruption of homoeostasis and lead to migraine.
Source: www.thelancet.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 2ELEVATEd hope for patients after migraine treatment failure - 2 month(s) ago
The emergence of calcitonin gene-related peptide (CGRP)-related medications has heralded a new era in migraine treatment. Numerous randomised controlled trials and real-world studies attest to the efficacy of anti-CGRP monoclonal antibodies and small-molecule CGRP receptor antagonists (gepants) in migraine preventive treatment, while gepants are also efficacious in acute treatment.
Source: www.thelancet.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 1Cristina Tassorelli: making a difference in headache research - 2 month(s) ago
Some observers might call Cristina Tassorelli a workaholic. Afterall, when we speak, she had sent her last e-mail late in the previous evening and, at 7am, had her first meeting of the day. Describing herself as highly motivated, curious, and energetic, she explains: “I’m never tired and I am in love with and believe in the work that I do”. Tassorelli is a Professor of Neurology and Dean of the Medical School at the University of Pavia, Italy. She also directs the Headache Science and Neurorehabilitation Centre and the Complex Unit of Neurorehabilitation at the IRCCS Neurological Institute C Mondino in Pavia.
Source: www.thelancet.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 12
Atogepant 60 mg once a day was safe, well tolerated, and showed significant and clinically relevant reductions in mean monthly migraine days compared with placebo across 12 weeks in patients with episodic migraine who had previously been failed by two to four classes of conventional oral preventive treatments. Atogepant might be an effective preventive treatment option for patients in this difficult-to-treat population.
Source: www.thelancet.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 5Genetics of migraine: complexity, implications, and potential clinical applications - 2 month(s) ago
Migraine is a common neurological disorder with large burden in terms of disability for individuals and costs for society. Accurate diagnosis and effective treatments remain priorities. Understanding the genetic factors that contribute to migraine risk and symptom manifestation could improve individual management. Migraine has a strong genetic basis that includes both monogenic and polygenic forms. Some distinct, rare, familial migraine subtypes are caused by pathogenic variants in genes involved in ion transport and neurotransmitter release, suggesting an underlying vulnerability of the excitatory–inhibitory balance in the brain, which might be exacerbated by disruption of homoeostasis and lead to migraine.
Source: www.thelancet.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 4Dysphagia after stroke: research advances in treatment interventions - 2 month(s) ago
After a stroke, most patients have dysphagia, which can lead to aspiration pneumonia, malnutrition, and adverse functional outcomes. Protective interventions aimed at reducing these complications remain the cornerstone of treatment. Dietary adjustments and oral hygiene help mitigate the risk of aspiration pneumonia, and nutritional supplementation, including tube feeding, might be needed to prevent malnutrition. Rehabilitative interventions aim to enhance swallowing function, with different behavioural strategies showing promise in small studies.
Source: www.thelancet.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 45Secondary stroke prevention in people with atrial fibrillation: treatments and trials - 2 month(s) ago
Atrial fibrillation is one of the most common cardiac arrhythmias and is a major cause of ischaemic stroke. Recent findings indicate the importance of atrial fibrillation burden (device-detected, subclinical, or paroxysmal and persistent or permanent) and whether atrial fibrillation was known before stroke onset or diagnosed after stroke for the risk of recurrence. Secondary prevention in patients with atrial fibrillation and stroke aims to reduce the risk of recurrent ischaemic stroke. Findings from randomised controlled trials assessing the optimal timing to introduce direct oral anticoagulant therapy after a stroke show that early start (ie, within 48 h for minor to moderate strokes and within 4–5 days for large strokes) seems safe and could reduce the risk of early recurrence.
Source: www.thelancet.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 2Increasing awareness of the need for brain health - 2 month(s) ago
Neurological disorders are affecting the lives of increasing numbers of people. New data from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) indicate that, in 2021, 3·4 billion people—more than 40% of the world’s population—had a condition affecting the nervous system, and that the associated health loss is increasing. The findings, together with several new initiatives, highlight the need for greater recognition of the burden of neurological disorders, and for urgent action.
Source: www.thelancet.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 50
Explore the current issue of The Lancet Neurology, a monthly journal covering international issues relevant to neurologists worldwide
Source: www.thelancet.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 4Fluctuations in Parkinson's disease: progress and challenges - 2 month(s) ago
Introduced in the 1960s, dopamine replacement therapy with levodopa remains the cornerstone of management for individuals with Parkinson’s disease.1 Patients on levodopa often have treatment-related complications, such as fluctuations and dyskinesia. Early data estimated that, for each year of exposure to levodopa, about 10% of people with Parkinson’s disease develop fluctuations and dyskinesia.2 In a prospective follow-up study over 10 years, 254 (35%) of 734 patients developed fluctuations.3 Regardless of the precise numbers, fluctuations are a source of disability for many individuals with Parkinson’s disease.
Source: www.thelancet.comCategories: General Medicine News, NeurologyTweet
In a Review, Heidi Sutherland and colleagues discuss the complexity, implications, and potential clinical applications of genetics in the management of migraine: https://t.co/RoWeKaArTw https://t.co/GPWBq2UnX0